congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Quizartinib
EHA 2024 | June 13-16, 2024
QuANTUM-First: Efficacy by age in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia
Oral
Quizartinib
EHA 2024 | June 13-16, 2024
QuANTUM-First: Efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia who received continuation therapy
Poster
Quizartinib
EHA 2024 | June 13-16, 2024
QuANTUM-First: Patient-reported outcomes in newly diagnosed Italicize FLT3-ITD+ acute myeloid leukemia patients receiving standard chemotherapy plus quizartinib or placebo
Oral
Valemetostat
EHA 2024 | June 13-16, 2024
Valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Efficacy by prior lines of treatment and last treatment outcome from the VALENTINE-PTCL01 study
Poster
Valemetostat
EHA 2024 | June 13-16, 2024
Valemetostat monotherapy in relapsed or refractory non-hodgkin lymphomas: A first-in-human phase 1 clinical trial